One Year Trial Evaluating Safety of Ozurdex With Eylea
Completed · Phase 4 · NCT03984110
Conditions: Diabetic Macular Edema
At a glance
- Research payments reported, 2025
- $260,700
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Texas Retina Associates (with The Emmes Company, LLC)
- Tested
- Ozurdex (drug), Eylea (drug)
- Dates
- Started 2019-06-11; completion 2022-10-27
- Results posted
- Not yet
One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)
From ClinicalTrials.gov, last updated 2024-04-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $260,700 in research payments for this study in 2025 (1 payments).
Products named: Ozurdex
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Retina Associates $260,700
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.